Claudio Sciarrone
Messina, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis).
Journal: Acta dermato-venereologica
Published: November 16, 2025
Letter: Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting-IL AD.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: June 05, 2025
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: May 22, 2025
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis).
Journal: Archives of dermatological research
Published: February 27, 2025
Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: December 05, 2024
Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and prior inefficacy of T helper 2 biologics: a propensity score-matched study.
Journal: Clinical and experimental dermatology
Published: October 11, 2024
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis).
Journal: The Journal of dermatological treatment
Published: October 10, 2024
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus.
Journal: Dermatology and therapy
Published: January 19, 2024
Chronic spontaneous urticaria treated with omalizumab: report of two cases.
Journal: The Journal of dermatological treatment
Published: November 22, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026